Aleksandra Franovic

Aleksandra Franovic has a diverse work experience in the field of biomedical research and development. Aleksandra is currently serving as the Vice President and Head of Biology at Kestrel Therapeutics since May 2022. Prior to this role, they held the position of Senior Director and Director of Translational Medicine at Kinnate Biopharma Inc. from October 2020 to May 2022. Before joining Kinnate Biopharma, they worked at Bristol Myers Squibb as a Principal Scientist and Senior Scientist in the Translational Medicine department from November 2019 to October 2020. Aleksandra also has experience at Celgene as a Senior Scientist in Translational Development & Diagnostics, at Guardant Health as a Medical Science Liaison, at Cardiff Oncology as a Senior Translational Scientist, and at IGNYTA, Inc. as a Scientist II and Scientist I in Oncology Discovery Research. Additionally, they have served as a Postdoctoral Fellow at the Moores Cancer Center and as a Research Associate at Health Canada. Throughout their career, Aleksandra Franovic has gained expertise in biology, translational medicine, oncology discovery research, and clinical and scientific affairs.

Aleksandra Franovic obtained a Ph.D. in Cellular and Molecular Medicine from the University of Ottawa in 2009. Prior to that, they completed a Bachelor of Applied Science in Chemical Engineering from the same university from 1998 to 2004. Additionally, they also earned a Bachelor of Science in Biochemistry from the University of Ottawa from 1998 to 2003.